keyword
MENU ▼
Read by QxMD icon Read
search

psychedelic psychotherapy

keyword
https://www.readbyqxmd.com/read/29152674/progress-and-promise-for-the-mdma-drug-development-program
#1
REVIEW
Allison A Feduccia, Julie Holland, Michael C Mithoefer
Pharmacotherapy is often used to target symptoms of posttraumatic stress disorder (PTSD), but does not provide definitive treatment, and side effects of daily medication are often problematic. Trauma-focused psychotherapies are more likely than drug treatment to achieve PTSD remission, but have high dropout rates and ineffective for a large percentage of patients. Therefore, research into drugs that might increase the effectiveness of psychotherapy is a logical avenue of investigation. The most promising drug studied as a catalyst to psychotherapy for PTSD thus far is 3,4-methylenedioxymethamphetamine (MDMA), commonly known as the recreational drug "Ecstasy...
November 20, 2017: Psychopharmacology
https://www.readbyqxmd.com/read/29126911/why-mdma-therapy-for-alcohol-use-disorder-and-why-now
#2
REVIEW
Ben Sessa
Alcohol use disorder represents a serious clinical, social and personal burden on its sufferers and a significant financial strain on society. Current treatments, both psychological and pharmacological are poor, with high rates of relapse after medical detoxification and dedicated treatment programs. The earliest historical roots of psychedelic drug-assisted psychotherapy in the 1950s were associated with Lysergic acid diethylamide (LSD)-assisted psychotherapy to treat what was then called, alcoholism. But results were varied and psychedelic therapy with LSD and other 'classical' psychedelics fell out of favour in the wake of socio-political pressures and cultural changes...
November 7, 2017: Neuropharmacology
https://www.readbyqxmd.com/read/29119217/psilocybin-with-psychological-support-for-treatment-resistant-depression-six-month-follow-up
#3
R L Carhart-Harris, M Bolstridge, C M J Day, J Rucker, R Watts, D E Erritzoe, M Kaelen, B Giribaldi, M Bloomfield, S Pilling, J A Rickard, B Forbes, A Feilding, D Taylor, H V Curran, D J Nutt
RATIONALE: Recent clinical trials are reporting marked improvements in mental health outcomes with psychedelic drug-assisted psychotherapy. OBJECTIVES: Here, we report on safety and efficacy outcomes for up to 6 months in an open-label trial of psilocybin for treatment-resistant depression. METHODS: Twenty patients (six females) with (mostly) severe, unipolar, treatment-resistant major depression received two oral doses of psilocybin (10 and 25 mg, 7 days apart) in a supportive setting...
November 8, 2017: Psychopharmacology
https://www.readbyqxmd.com/read/28768346/-psychotherapy-with-adjuvant-use-of-serotonergic-psychoactive-substances-possibilities-and-challenges
#4
Tomislav Majić, Henrik Jungaberle, Timo T Schmidt, Andrea Zeuch, Leo Hermle, Jürgen Gallinat
Background Recently, scientific interest in the therapeutic potential of serotonergic and psilocybin hallucinogens (psychedelics) such as lysergic acid diethylamide (LSD) and entactogens like 3,4-methylendioxymethamphetamine (MDMA) within the framework of psychotherapy has resumed. The present article provides an overview on the current evidence on substance-assisted psychotherapy with these substances. Method A selective search was carried out in the PubMed and Cochrane Library including studies investigating the clinical use of serotonergic psychoactive substances since 2000...
July 2017: Fortschritte der Neurologie-Psychiatrie
https://www.readbyqxmd.com/read/28443617/the-therapeutic-potential-of-psychedelic-drugs-past-present-and-future
#5
Robin L Carhart-Harris, Guy M Goodwin
Plant-based psychedelics, such as psilocybin, have an ancient history of medicinal use. After the first English language report on LSD in 1950, psychedelics enjoyed a short-lived relationship with psychology and psychiatry. Used most notably as aids to psychotherapy for the treatment of mood disorders and alcohol dependence, drugs such as LSD showed initial therapeutic promise before prohibitive legislature in the mid-1960s effectively ended all major psychedelic research programs. Since the early 1990s, there has been a steady revival of human psychedelic research: last year saw reports on the first modern brain imaging study with LSD and three separate clinical trials of psilocybin for depressive symptoms...
October 2017: Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28196428/the-association-of-psychedelic-use-and-opioid-use-disorders-among-illicit-users-in-the-united-states
#6
Vincent D Pisano, Nathaniel P Putnam, Hannah M Kramer, Kevin J Franciotti, John H Halpern, Selma C Holden
BACKGROUND: Preliminary studies show psychedelic compounds administered with psychotherapy are potentially effective and durable substance misuse interventions. However, little is known about the association between psychedelic use and substance misuse in the general population. This study investigated the association between psychedelic use and past year opioid use disorders within illicit opioid users. METHODS: While controlling for socio-demographic covariates and the use of other substances, the relationship between classic psychedelic use and past year opioid use disorders was analyzed within 44,000 illicit opioid users who completed the National Survey on Drug Use and Health from 2008 to 2013...
May 2017: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/28019026/psychedelics-as-medicines-an-emerging-new-paradigm
#7
REVIEW
D E Nichols, M W Johnson, C D Nichols
Scientific interest in serotonergic psychedelics (e.g., psilocybin and LSD; 5-HT2A receptor agonists) has dramatically increased within the last decade. Clinical studies administering psychedelics with psychotherapy have shown preliminary evidence of robust efficacy in treating anxiety and depression, as well as addiction to tobacco and alcohol. Moreover, recent research has suggested that these compounds have potential efficacy against inflammatory diseases through novel mechanisms, with potential advantages over existing antiinflammatory agents...
February 2017: Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/27435062/ayahuasca-enhances-creative-divergent-thinking-while-decreasing-conventional-convergent-thinking
#8
K P C Kuypers, J Riba, M de la Fuente Revenga, S Barker, E L Theunissen, J G Ramaekers
INTRODUCTION: Ayahuasca is a South American psychotropic plant tea traditionally used in Amazonian shamanism. The tea contains the psychedelic 5-HT2A receptor agonist N,N-dimethyltryptamine (DMT), plus β-carboline alkaloids with monoamine oxidase-inhibiting properties. Increasing evidence from anecdotal reports and open-label studies indicates that ayahuasca may have therapeutic effects in treatment of substance use disorders and depression. A recent study on the psychological effects of ayahuasca found that the tea reduces judgmental processing and inner reactivity, classic goals of mindfulness psychotherapy...
September 2016: Psychopharmacology
https://www.readbyqxmd.com/read/27392130/from-psychiatry-to-flower-power-and-back-again-the-amazing-story-of-lysergic-acid-diethylamide
#9
Hermann A M Mucke
Among the psychedelic drugs that enjoyed a period of popularity in psychiatric research during the 1950s and 1960s, lysergic acid diethylamide (LSD) is the most prominent one. Psychiatrists of that time had seen LSD not only as a tool for psychotherapy but also as a potential therapeutic for anxiety, depression, alcohol abuse, autism, and even schizophrenia. When it became a quasi-religious epitome of the Hippie counterculture in the mid 1960s, and cases of what we now call hallucinogen persisting perception disorder and acute psychotic "flashbacks" mounted, authorities moved to make LSD illegal...
July 8, 2016: Assay and Drug Development Technologies
https://www.readbyqxmd.com/read/27378878/ego-dissolution-and-psychedelics-validation-of-the-ego-dissolution-inventory-edi
#10
Matthew M Nour, Lisa Evans, David Nutt, Robin L Carhart-Harris
AIMS: The experience of a compromised sense of "self", termed ego-dissolution, is a key feature of the psychedelic experience. This study aimed to validate the Ego-Dissolution Inventory (EDI), a new 8-item self-report scale designed to measure ego-dissolution. Additionally, we aimed to investigate the specificity of the relationship between psychedelics and ego-dissolution. METHOD: Sixteen items relating to altered ego-consciousness were included in an internet questionnaire; eight relating to the experience of ego-dissolution (comprising the EDI), and eight relating to the antithetical experience of increased self-assuredness, termed ego-inflation...
2016: Frontiers in Human Neuroscience
https://www.readbyqxmd.com/read/27354909/lysergic-acid-diethylamide-a-drug-of-use
#11
REVIEW
Saibal Das, Preeti Barnwal, Anand Ramasamy, Sumalya Sen, Somnath Mondal
Lysergic acid diethylamide (LSD), described as a classical hallucinogen, began its journey from the middle of the last century following an accidental discovery. Since then, it was used as a popular and notorious substance of abuse in various parts of the world. Its beneficial role as an adjunct to psychotherapy was much unknown, until some 'benevolent' experiments were carried out over time to explore some of its potential uses. But, many of its effects were unclear and seemed to be a psychedelic enigma. In this review article, we have described the receptor pharmacology, mechanism of action, effects and adverse effects of LSD on the normal body system...
June 2016: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/27084302/lsd-modulates-music-induced-imagery-via-changes-in-parahippocampal-connectivity
#12
Mendel Kaelen, Leor Roseman, Joshua Kahan, Andre Santos-Ribeiro, Csaba Orban, Romy Lorenz, Frederick S Barrett, Mark Bolstridge, Tim Williams, Luke Williams, Matthew B Wall, Amanda Feilding, Suresh Muthukumaraswamy, David J Nutt, Robin Carhart-Harris
Psychedelic drugs such as lysergic acid diethylamide (LSD) were used extensively in psychiatry in the past and their therapeutic potential is beginning to be re-examined today. Psychedelic psychotherapy typically involves a patient lying with their eyes-closed during peak drug effects, while listening to music and being supervised by trained psychotherapists. In this context, music is considered to be a key element in the therapeutic model; working in synergy with the drug to evoke therapeutically meaningful thoughts, emotions and imagery...
July 2016: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/27067625/novel-psychopharmacological-therapies-for-psychiatric-disorders-psilocybin-and-mdma
#13
REVIEW
Michael C Mithoefer, Charles S Grob, Timothy D Brewerton
4-phosphorloxy-N,N-dimethyltryptamine (psilocybin) and methylenedioxymethamfetamine (MDMA), best known for their illegal use as psychedelic drugs, are showing promise as therapeutics in a resurgence of clinical research during the past 10 years. Psilocybin is being tested for alcoholism, smoking cessation, and in patients with advanced cancer with anxiety. MDMA is showing encouraging results as a treatment for refractory post-traumatic stress disorder, social anxiety in autistic adults, and anxiety associated with a life-threatening illness...
May 2016: Lancet Psychiatry
https://www.readbyqxmd.com/read/26841800/psychedelics
#14
REVIEW
David E Nichols
Psychedelics (serotonergic hallucinogens) are powerful psychoactive substances that alter perception and mood and affect numerous cognitive processes. They are generally considered physiologically safe and do not lead to dependence or addiction. Their origin predates written history, and they were employed by early cultures in many sociocultural and ritual contexts. After the virtually contemporaneous discovery of (5R,8R)-(+)-lysergic acid-N,N-diethylamide (LSD)-25 and the identification of serotonin in the brain, early research focused intensively on the possibility that LSD and other psychedelics had a serotonergic basis for their action...
April 2016: Pharmacological Reviews
https://www.readbyqxmd.com/read/26257162/lsd-enhances-the-emotional-response-to-music
#15
M Kaelen, F S Barrett, L Roseman, R Lorenz, N Family, M Bolstridge, H V Curran, A Feilding, D J Nutt, R L Carhart-Harris
RATIONALE: There is renewed interest in the therapeutic potential of psychedelic drugs such as lysergic acid diethylamide (LSD). LSD was used extensively in the 1950s and 1960s as an adjunct in psychotherapy, reportedly enhancing emotionality. Music is an effective tool to evoke and study emotion and is considered an important element in psychedelic-assisted psychotherapy; however, the hypothesis that psychedelics enhance the emotional response to music has yet to be investigated in a modern placebo-controlled study...
October 2015: Psychopharmacology
https://www.readbyqxmd.com/read/25818246/mdma-assisted-therapy-a-new-treatment-model-for-social-anxiety-in-autistic-adults
#16
RANDOMIZED CONTROLLED TRIAL
Alicia L Danforth, Christopher M Struble, Berra Yazar-Klosinski, Charles S Grob
The first study of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for the treatment of social anxiety in autistic adults commenced in the spring of 2014. The search for psychotherapeutic options for autistic individuals is imperative considering the lack of effective conventional treatments for mental health diagnoses that are common in this population. Serious Adverse Events (SAEs) involving the administration of MDMA in clinical trials have been rare and non-life threatening. To date, MDMA has been administered to over 1133 individuals for research purposes without the occurrence of unexpected drug-related SAEs that require expedited reporting per FDA regulations...
January 4, 2016: Progress in Neuro-psychopharmacology & Biological Psychiatry
https://www.readbyqxmd.com/read/25670401/peak-experiences-and-the-afterglow-phenomenon-when-and-how-do-therapeutic-effects-of-hallucinogens-depend-on-psychedelic-experiences
#17
REVIEW
Tomislav Majić, Timo T Schmidt, Jürgen Gallinat
Interest in the therapeutic potential of psychedelic substances has recently resumed. During an early phase of human psychedelic research, their therapeutic application in different pathologies had been suggested, and the first evidence for efficacy was provided. The range of recent clinical applications of psychedelics spans from cluster headaches and obsessive-compulsive disorder to addiction and the treatment of fear and anxiety in patients suffering from terminal illness, indicating potentially different therapeutic mechanisms...
March 2015: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/25563447/crisis-intervention-related-to-the-use-of-psychoactive-substances-in-recreational-settings-evaluating-the-kosmicare-project-at-boom-festival
#18
Maria Carmo Carvalho, Mariana Pinto de Sousa, Paula Frango, Pedro Dias, Joana Carvalho, Marta Rodrigues, Tania Rodrigues
Kosmicare project implements crisis intervention in situations related to the use of psychoactive substances at Boom Festival (Portugal). We present evaluation research that aims to contribute to the transformation of the project into an evidence-based intervention model. It relies on harm reduction and risk minimization principles, crisis intervention models, and Grof's psychedelic psychotherapy approach for crisis intervention in situations related to unsupervised use of psychedelics. Intervention was expected to produce knowledge about the relation between substance use and mental health impact in reducing potential risk related to the use of psychoactive substances and mental illness, as well as an impact upon target population's views of themselves, their relationship to substance use, and to life events in general...
2014: Current Drug Abuse Reviews
https://www.readbyqxmd.com/read/24830183/history-and-future-of-the-multidisciplinary-association-for-psychedelic-studies-maps
#19
Amy Emerson, Linnae Ponté, Lisa Jerome, Rick Doblin
This article describes the teenage vision of the founder of the Multidisciplinary Association for Psychedelic Studies (MAPS) that humanity's future would be aided by the therapeutic and spiritual potential of psychedelic substances. The article traces the trajectory of MAPS from inception in 1986 to its present, noting future goals with respect to research, outreach, and harm reduction. MAPS was created as a non-profit psychedelic pharmaceutical company in response to the 1985 scheduling of 3,4-methylenedioxymethamphetamine (MDMA)...
January 2014: Journal of Psychoactive Drugs
https://www.readbyqxmd.com/read/24762477/the-metaphysical-combat-with-death-in-the-terminally-ill-and-the-psychedelic-trail
#20
EDITORIAL
Varsha Dutta
No abstract text is available yet for this article.
January 2014: Journal of Cancer Research and Therapeutics
keyword
keyword
72981
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"